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Abstract 
 
Background 
Genome-wide association studies (GWAS) have shown a polygenic 
component to the risk of schizophrenia. The disorder is associated 
with impairments in general cognitive ability that also have a 
substantial genetic contribution. No study has determined whether 
cognitive impairments can be attributed to schizophrenia’s 
polygenic architecture using data from GWAS.  
 
Methods 
Members of the Lothian Birth Cohort 1936 (LBC1936, N=937) were 
assessed using the Moray House Test (MHT) at age 11 and with the 
MHT and a further cognitive battery at age 70. To create polygenic 
risk scores for schizophrenia, we obtained data from the latest 
GWAS of the Psychiatric GWAS Consortium on Schizophrenia (PGC-
SCZ). Schizophrenia polygenic risk profile scores were calculated 
using information from the PGC-SCZ GWAS.  
 
Results 
In LBC1936, polygenic risk for schizophrenia was negatively 
associated with IQ at age 70, but not age 11. Greater polygenic risk 
for schizophrenia was associated with more relative decline in IQ 
between these ages. These findings were maintained when the 
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results of LBC1936 were combined with that of the independent 
Lothian Birth Cohort 1921 (N=517) in a meta-analysis.  
 
Conclusions 
Increased polygenic risk of schizophrenia is associated with lower 
cognitive ability at age 70, and greater relative decline in general 
cognitive ability between the ages of 11 and 70. Common genetic 
variants may underlie both cognitive ageing and risk of 
schizophrenia.  
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Introduction 
 
Schizophrenia is a familial disorder in which genetic factors account 
for approximately 80% of the total variation in liability(1). 
Schizophrenia is frequently associated with lifelong disability and 
with impaired cognitive test performance that is not effectively 
treated with current antipsychotic treatments(2). Reduced general 
cognitive ability has also been found in children who later develop 
schizophrenia(3-5), in people at high genetic risk of psychosis(6, 7) 
and studies of unaffected adult relatives(8). Bivariate genetic 
studies (in affected patients and their families) suggest that the 
phenotypic correlation between cognitive ability and risk of 
schizophrenia is substantial and up to 92% of their covariance is 
due to common genetic factors(9, 10). These shared genetic causes 
have not yet been attributed to sets of specific SNPs. Whether these 
genetic risk factors confer a long-term, stable deficit in cognitive 
ability, or greater risk of cognitive decline over time, or both, is also 
not known. 
 
General cognitive ability is substantially stable over time, with a 
correlation of >0.6 between measures of IQ taken at age 11 and 
70(11). General cognitive ability also has a strong genetic basis(12, 
13). By adolescence and throughout adulthood, well over 50% of its 
variation is due to genetic factors(12). Using genome-wide SNP 
data, we have estimated that common variants account for 24% of 
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the change in general cognitive ability from age 11 to age 70. These 
findings warrant a search for genetic variants that influence both 
the enduring stable trait of cognitive ability, and its change across 
the life course after childhood.  
 
In the present study we test the hypothesis that having more of the 
common, risk-associated genetic variants for schizophrenia is 
associated with lower cognitive ability in childhood and old age, and 
relatively more decline in between. Whilst a relationship between 
genetic risk of schizophrenia and cognition has been based largely 
on studies of affected individuals, we sought to address this issue in 
a sample of individuals from the healthy population.  We studied the 
Lothian Birth Cohort 1936(14) whose participants have cognitive 
function data in childhood and old age, and genome-wide SNP data. 
We used information from the latest-available Psychiatric GWAS 
consortium (PGC-SCZ) release to provide individual polygenic risk 
profile scores(15).  
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Materials and Methods 
 
Subjects 
The Lothian Birth Cohort 1936 (LBC1936) comprises 1091 
community-dwelling individuals without dementia (548 men and 
543 women), residing in or around the city of Edinburgh, 
Scotland(14, 16). Most of the LBC1936 had participated in the 
Scottish Mental Survey 1947 (SMS1947) at a mean age of 10.9 
years and then in a follow up assessment approximately 59 years 
later at a mean age of 69.5 years old (SD 0.8). These assessments 
are referred to as ages 11 and 70 throughout. All subjects were 
asked questions about their medical history. 
 
Cognitive testing 
Most LBC1936 participants undertook the Moray House Test (MHT) 
at age 11(14). They re-took the MHT at about age 70. The MHT is a 
group-administered, paper-and-pencil test that has a time limit of 
45 minutes and has a preponderance of verbal reasoning items with 
some arithmetical and abstract items also. MHT scores were 
converted into an IQ-type scale, with a mean of 100 and SD = 15, 
as we have done elsewhere(17). At age 70, participants completed 
an additional cognitive test battery of psychometric tests from the 
Wechsler Adult Intelligence Scale (WAIS)-III(18) and Wechsler 
Memory Scale (WMS)-III(19), including Digit Symbol Coding, Block 
Design, Matrix Reasoning, Digit Span Backwards, Symbol Search 
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and Letter-number sequencing. The additional tasks resulted in a 
measure of cognitive ability at age 70 that had a greater number of 
fluid-type tasks. Principal Component Analysis (PCA)-derived scores 
were then computed for general cognitive ability, memory, and 
processing speed(20).  
 
Genotyping and risk profile score calculation 
Details of the GWAS sample collection, processing and quality 
control have been described elsewhere(12). Genomic DNA was 
extracted from venous blood of members of LBC1936. Genotyping 
was conducted at the Wellcome Trust Clinical Research Facility, 
Edinburgh, United Kingdom (www.wtcrf.ed.ac.uk) and used the 
Illumina 610-Quadv1 whole-genome SNP array (San Diego, CA, 
USA). SNPs were excluded from the polygenic analysis where the 
minor allele frequency was less than 2%, if the call rate was less 
than 98% or if the Chi-squared test for Hardy–Weinberg Equilibrium 
was less than 0.001. Strand ambiguous SNPs were also removed. 
The resulting SNP set was then used to calculate four 
multidimensional scaling (MDS) components to assess for 
population stratification and adjust for this in later analyses. The 
data were then imputed to HapMap version 3 using MACH software 
(http://www.sph.umich.edu/csg/abecasis/MACH) and then 
converted back to plink (map/ped) format for later analysis. 
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Summary results from the most recent international GWAS of 9,394 
individuals with schizophrenia(21) and 12,462 controls were 
obtained from PGC-SCZ. Details of the methods used by the 
consortium are given elsewhere(21). Polygenic profile scores were 
calculated according to the methods described by Purcell et al(15). 
Four lists of significant SNPs were generated from the PGC-SCZ 
association data, at significance thresholds of p<0.5, p<0.1, p<0.05 
and p<0.01. These were used to select SNPs with a minor allele 
frequency of at least 2% from our LBC1936 GWAS data set, 
resulting in four separate files that contained the genotypes of each 
individual. In order to identify polygenic effects due to independent 
SNPs in linkage equilibrium with one another, each SNP set was 
then pruned using the variance inflation factor which is equivalent 
to 1/(1-R2) (where R is the multiple regression coefficient for a SNP 
being regressed on all other SNPs simultaneously). Linkage 
equilibrium-based SNP pruning was conducted in a sliding window 
of 50 SNPs with each calculation performed iteratively by moving 
the window by five SNPs. SNPs were conservatively selected on the 
basis of a variance inflation factor of 2 or less. Finally, to obtain 
polygenic risk profile scores for schizophrenia, these four SNP sets 
were then scored using the sum of the number of reference alleles 
multiplied by the logarithm of the odds ratio for schizophrenia 
across the whole genome. 
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All analyses were performed in Plink with the exception of 
imputation to HapMap version 3 and data manipulation, which were 
performed in Mach (www.sph.umich.edu/csg/abecasis/MACH) and R 
software, respectively. 
 
Statistical analyses 
All statistical analyses were conducted in the R statistical software 
package (http://www.r-project.org/) using linear regression models 
that were adjusted for the first four MDS components measuring 
population stratification, for gender, and for a previous history of 
diabetes, stroke or hypertension as these conditions have 
previously been shown adversely to affect cognition or cognitive 
ageing(22-24). We examined the association between polygenic risk 
profile scores for schizophrenia at all four thresholds and cognitive 
ability in childhood IQ from the MHT at age 11) and cognitive ability 
in old age (IQ from the MHT at age 70 and then from six tests at 
age 70). In total, nine hundred and thirty seven people provided 
data for analysis.  
 
We examined the relationship between polygenic risk profile scores 
for schizophrenia and participant’s relative cognitive change 
between childhood and old age. This long-term cognitive change 
was derived as follows. The relationship between IQ at age 11 and 
70 could be summarized using a linear regression model in which 
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the residual value reflected the observed deviation in IQ at age 70 
based on that predicted by IQ at age 11. They represent an 
estimate of cognitive change for each LBC1936 participant with the 
relevant data. Negative values reflect a decline in function relative 
to that of others in the sample. Change scores were also estimated 
for general cognitive ability after adjustment for age 11 IQ. 
 
Replication sample 
Significant relationships between polygenic risk for schizophrenia 
and cognitive ability or cognitive ability change were then examined 
in the smaller Lothian Birth Cohort of 1921 (LBC1921)(25). The 
LBC1921 sample contributed 517 individuals to the current analysis 
who participated in the Scottish Mental Survey of 1932 when they 
were aged 11. The MHT number No. 12 was administered at age 11 
and again at age 79, when Raven’s(26) Standard Progressive 
Matrices, verbal Fluency(27) and Logical Memory(28) tests were 
also administered. General cognitive ability was measured using the 
MHT alone, and from the first principal component of the four 
cognitive tests at age 79. Processing methods and the subsequent 
analyses, including GWAS, were nearly identical to the methods 
used in LBC1936. The analyses were all adjusted for gender, the 
first 4 GWAS-MDS components and for the presence of a previous 
diagnosis of diabetes, hypertension or vascular disease.  
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In addition for testing for replication of significant findings across 
the two cohorts LBC1936 and LBC1921, we also conducted a meta-
analysis of the results from the two studies. A fixed effects model 
was used which used the standardized regression coefficients were 
weighted by the inverse of their squared standard error and pooled 
to provide a summary estimate across both cohorts.  
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Results 
A total sample of 937 (479 women and 458 men) individuals 
contributed both genome-wide and cognitive data to the analysis of 
the LBC1936, none of whom were known to suffer from 
schizophrenia. Three hundred and sixty-nine people (39%) had a 
history of hypertension, 82 had a history of diabetes (9%), and 46 
(5%) had a history of previous stroke. We adjusted for these 
variables in all subsequent analyses. 
 
Relationship of polygenic score to cognition 
Polygenic risk for schizophrenia (derived separately using four 
significance thresholds) was not associated with IQ at age 11 
(Supplementary Table 1). Polygenic risk for schizophrenia showed a 
weak, non-significant association with MHT-derived IQ at age 70 at 
p-thresholds of 0.5 (Table 1: beta = -0.06, p = 0.09) and 0.1 
(Table 1: beta = -0.06, p = 0.08). Polygenic risk for schizophrenia 
was significantly associated with general cognitive ability at age 70 
as based on the six non-verbal subtests from the Wechsler battery, 
at all four GWAS thresholds (range of p-values 0.005 to 0.02, Table 
1).   
 
Relationship of polygenic score to change in cognition 
Greater polygenic risk for schizophrenia was associated with 
relatively greater decline in IQ from age 11 to age 70 (based on 
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MHT scores adjusted for IQ at age 11) at the GWAS threshold of 
p=0.01 (beta = -0.07, p = 0.03). A trend was observed for the 
threshold of p=0.1 (Table 2: beta = -0.07, p = 0.05). When lifetime 
cognitive change was derived from the six Wechsler non-verbal 
tests at age 70 adjusted for IQ at age 11, polygenic risk for 
schizophrenia was associated with lower than expected general 
cognitive ability at all four GWAS significance thresholds (range of 
p-values 0.004 to 0.008, Table 2). Judged by the change in the 
model R2 statistic, the proportion of variance in cognitive ability 
change between age 11 and 70 (using the Wechsler tests) 
explained by polygenic risk for schizophrenia was between 0.8% at 
a GWAS threshold of P = 0.5 to 0.9% at the threshold of P = 0.005.  
 
Replication in LBC1921 
Three out of four of the significant associations between polygenic 
risk for schizophrenia and general cognitive ability at age 70 in 
LBC1936 were in the same direction in the smaller LBC1921 cohort 
at age 79. Polygenic risk for schizophrenia at the GWAS threshold of 
p = 0.01 additionally showed a significant negative association with 
general cognitive ability at age 79 (Table 3, Standardised beta = -
0.11, p = 0.03) in LBC1921. This finding replicated the association 
found in LBC1936 in both direction and significance.  
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The significant negative association between polygenic risk of 
schizophrenia at a threshold of p = 0.01 and relative change in 
cognitive ability measured using the MHT in LBC1936 was also in 
the same direction in LBC1921 (standardised beta = -0.04, p = 
0.38). When IQ was determined using four tests in LBC1921, the 
negative associations between polygenic risk of schizophrenia and 
change in cognitive ability remained in the same direction for all but 
the GWAS threshold of p = 0.5 (Table 3). None of these findings 
were individually significant in LBC1921 (which has a much smaller 
sample size). 
 
Fixed effects meta-analysis using data from both cohorts showed a 
significant negative association between polygenic risk for 
schizophrenia and general cognitive ability in the eighth decade 
using the composite measure derived from four or six separate 
tests (Table 3: significant negative association with general 
cognitive ability at GWAS thresholds 0.1, 0.05 and 0.01). Polygenic 
risk for schizophrenia was also significantly and negatively 
associated with change in cognitive ability from 11 to 70 or 79 using 
the MHT (GWAS threshold p = 0.01: standardised beta = -0.06, p = 
0.036). This negative association was also found using the estimate 
of change in cognitive ability based upon the four or six tests at 
GWAS thresholds of 0.1, 0.05 and 0.01 (Table 3).  
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Discussion  
Greater polygenic risk for schizophrenia is associated with lower 
fluid-type general cognitive ability at age 70, but not at age 11. 
Furthermore, greater polygenic risk for schizophrenia is associated 
with a greater relative decline in general cognitive functioning 
between age 11 and age 70. These results were significant with the 
verbal-reasoning-dominated Moray House Test was used and when 
using a more extensive cognitive battery that incorporated non-
verbal, fluid-intelligence-type tests from the Wechsler battery.  
 
The association of polygenic risk for schizophrenia with cognitive 
ability at age 70 independently replicated partially in LBC1921 at 
age 79, at the GWAS threshold of p = 0.01. The direction of each 
statistically significant effect in LBC1936 was broadly replicated in 
LBC1921 for all but the most liberal of the GWAS thresholds (p = 
0.5). Meta-analysis of the findings from both LBC1921 and LBC1936 
also supported a significant negative association between polygenic 
risk for schizophrenia and both general cognitive ability in old age 
and cognitive ability change from childhood to old age.  
 
Cognition is impaired in schizophrenia(29) and more recent studies 
have demonstrated that cognitive deficits may be seen pre-morbidly 
and in the unaffected close relatives of people with schizophrenia(5, 
8). We are not aware of any studies that have serially-measured 
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cognition over time in a population-based cohort and then related 
these measurements to polygenic risk of schizophrenia. These 
cognitive changes occurred between age 11 and the eighth decade 
of life, and the precise timing and trajectory of these changes could 
not be determined in the current study. Therefore, whilst these 
changes are likely to be related to brain plasticity, it is not possible 
to identify whether the changes were related specifically to 
neurodevelopmental factors. Because the LBC1936 is a year-of-
birth sample of mainly healthy people living in the community, 
these findings suggest that common genetic risk variants for 
schizophrenia may accelerate cognitive ageing independent of the 
clinical illness.  
 
Studies of specific genetic risk factors, such as those identified in 
DISC1 or NRG1, as well as some genome-wide significant variants, 
have demonstrated an association between the risk allele and 
cognitive impairment in one or more domains(30-32). It is likely, 
however, that these variants individually capture less than 1% of 
the total risk to schizophrenia and cumulatively less than 5% of the 
total risk to the disorder(21). A significant proportion of the ‘missing 
heritability’ to schizophrenia may lie in the variants that do not 
survive multiple testing corrections across the whole genome in 
GWAS studies. Recently Lee et al have shown that up to 25% of the 
risk for schizophrenia can be attributed to variants that do not reach 
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whole-genome significance(33). This implies that a polygenic 
approach to estimating individualized risk, taking in SNPs with p-
vales <0.5, may be able to provide better phenotype predictions. 
This may be especially true in adult samples where general 
cognitive ability may be more strongly influence by genetic factors 
than in children(34). 
 
The current findings suggest that common risk variants for 
schizophrenia are in combination associated with greater decline in 
general cognitive ability between age 11 and age 70. This builds 
upon a large body of literature showing a decline in general 
cognitive function over time in people at high genetic risk who later 
develop schizophrenia(3, 7), and upon studies that show a 
reduction over time in cognitive function in well relatives and 
affected patients. The proportion of genetic variance for 
schizophrenia shared with that for premorbid intelligence is 
modest(35) and less than initially expected(9). Fowler et al (2012) 
suggested that the phenotypic correlation between intelligence and 
schizophrenia might be caused by the onset of psychosis. However, 
that study was not in a position to test the phenotypic correlation 
between psychosis and age-related cognitive change, or the 
proportion of genetic variance that they share. The present study 
points to cognitive change and not prior cognition as the companion 
of schizophrenia risk.  
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Identifying traits that are genetically correlated with schizophrenia 
may also have statistical advantages for the identification of new 
quantitative trait loci(36). It is also possible, as GWAS samples 
increase and more of the heritability is captured by genotyping, that 
polygenic profiling will capture a greater proportion of variance in 
risk of schizophrenia. Assuming a constant genetic correlation with 
cognitive ability, the proportion of variance in cognition and 
cognitive ageing explained by polygenetic risk of schizophrenia can 
also be expected to increase. This has important implications for the 
eventual clinical usefulness of polygenetic profiling in schizophrenia, 
although future studies will also need to address the diagnostic 
specificity of these findings.  
 
 
The present study has some potential limitations. Firstly, the 
cognitive test applied at age 11 (the Moray House Test) is not one 
that is in common use today and contemporary tests of cognition 
may have provide more accurate estimate of cognitive ability. 
However, previous studies have demonstrated a very high 
correlation (0.8 or more) between the MHT scores and individually 
administered cognitive assessments in childhood (Binet tests)(37) 
and old age (Wechsler tests)(38) suggesting that its use as a 
measure of general intelligence has concurrent validity across the 
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life course(39). Secondly, some of the results reported here would 
not survive stringent multiple testing corrections. However, the 
study’s principal hypothesis concerned an association between 
polygenic risk profile scores and a decline in general cognitive 
ability, and was supported using data from both the MHT and a 
general cognitive factor derived from six non-verbal Wechsler 
subtests. The finding of greater cognitive ageing using the general 
cognitive battery would have survived false discovery rate 
correction(40) at all four GWAS p-values thresholds. It should 
thirdly be noted that the effects sizes reported in the current study 
are small and do not imply that the overlap in genetic architecture 
between cognitive ability, cognitive ageing and schizophrenia is 
substantial.  
 
The failure to replicate the significant association in LBC1936 
between polygenic risk for schizophrenia and change in cognitive 
ability in LBC1921 may also be seen as a limitation. The 
substantially smaller sample size in LBC1921 compared to LBC1936, 
as well as their more advanced years and greater comorbidity, may 
explain this apparent discrepancy. Nevertheless, the meta-analysis 
of findings from both studies supports our overall findings and 
conclusions. 
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The current study finds that polygenic risk for schizophrenia 
determined from GWAS contributes significantly to variation in the 
age-related decline of general cognitive ability in a community-
dwelling sample assessed at age 11 and age 70. These findings 
were made in predominantly healthy, community-dwelling 
individuals and were therefore not simply due to the effects of 
chronic psychosis or its treatment. Cognitive ageing is growing in 
importance as a personal, social and economic burden on 
societies(41). It appears to be partly heritable(11), yet the specific 
genes are elusive(42). This new clue to the location of some of the 
genetic variation in cognitive ageing could aid the mechanistic 
understanding of both cognitive ageing and schizophrenia, and the 
link between them. 
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Table 1: Polygene scores and cognitive ability age 70 in 937 people from LBC1936 
 
Threshold Cognitive ability at age 70 from MHT Cognitive ability at age 70 from ability from 
six Wechsler tests 
P = 0.5 Beta = -0.06, t = -1.68, p = 0.09, R2 = 0.3 Beta = -0.10, t = -2.80, p = 0.005, R2 = 0.8 
P = 0.1 Beta = -0.06, t = -1.74, p = 0.08, R2 = 0.3 Beta = -0.09, t = -2.46, p = 0.01, R2 = 0.6 
P = 0.05 Beta = -0.03, t = -0.97, p = 0.33, R2 = 0.1 Beta = -0.08, t = -2.45, p = 0.01, R2 = 0.6 
P = 0.01 Beta = -0.05, t = -1.40, p = 0.16, R2 = 0.2 Beta = -0.08, t = -2.30, p = 0.02, R2 = 0.6 
 
Beta: Standardized regression coefficient representing change in dependent variable for unit change in polygene 
profile scores, where both are measured in standard deviation units. R2: Estimate of variance in cognitive ability 
explained by polygene score in % 
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Table 2: Polygenic scores and cognitive ability change between age 11 and age 70 in 937 people from 
LBC1936 
 
Threshold Change in cognitive ability from 11 to 70 
from MHT 
Change in cognitive ability from 11 to 70 from 
six Wechsler tests 
P = 0.5 Beta = -0.04, t =-1.12, p = 0.26, R2 = 0.1 Beta = -0.08, t = -2.44, p = 0.015, R2 = 0.6 
P = 0.1 Beta = -0.07, t = -1.93, p = 0.05, R2 = 0.4 Beta = -0.09, t = -2.68, p = 0.007, R2 = 0.8 
P = 0.05 Beta = -0.04, t = -1.19, p = 0.23, R2 = 0.2 Beta = -0.10, t = -2.89, p = 0.004, R2 = 0.9 
P = 0.01 Beta = -0.07, t = -2.14, p = 0.03 , R2 = 0.5 Beta = -0.10, t = -2.93, p = 0.003, R2 = 0.9 
 
Beta: Standardized regression coefficient. R2: Estimate of variance in cognitive ability change explained by 
polygene score. R2: Estimate of variance in cognitive ability explained by polygene score in % 
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Table 3: Polygenic scores and cognitive ability in 517 people from LBC1921 and LBC1921 and LBC1936 
combined (N=1,434) 
 
Threshold 
Cognitive ability at age 79 from four tests in 
LBC1921 
Meta-analysis of LBC1921 and LBC1936 
Fixed Effects Estimate 
P = 0.5 Beta = 0.045, SE = 0.050, t = 0.91, p =0.36 Beta = -0.05, z = -1.92, p = 0.054 
P = 0.1 Beta = -0.083, SE = 0.0497, t = -1.66, p = 0.097 Beta = -0.08, z = -3.43, p = 0.0006 
P = 0.05 Beta = -0.065, SE = 0.050, t = -1.30, p = 0.20 Beta = -0.08, z = -2.68, p = 0.007 
P = 0.01 Beta = -0.11, SE = 0.0519, t = -2.17, p = 0.03 Beta = -0.09, z = -3.08, p = 0.002 
 
Change in cognitive ability from 11 to 79 from 
MHT in LBC1921 
Meta-analysis of LBC1921 and LBC1936 
Fixed Effects Estimate 
P = 0.01 Beta = -0.04, SE = 0.050, t = -0.89, p = 0.38 Beta = -0.06, z = -2.10, p = 0.036 
 
Change in cognitive ability from 11 to 79 from 
four tests in LBC1921 
Meta-analysis of LBC1921 and LBC1936 
Fixed Effects Estimate 
P = 0.5 Beta = 0.05, SE = 0.049, t = 0.99, p = 0.32 Beta = -0.04, z = -1.42, p = 0.15 
P = 0.1 Beta = -0.03, SE = 0.049, t = -0.65, p = 0.52 Beta = -0.07, z = -2.52, p = 0.01 
P = 0.05 Beta = -0.02, SE = 0.050, t = -0.40, p = 0.69 Beta = -0.07, z = -2.66, p = 0.008 
P = 0.01 Beta = -0.06, SE = 0.052, t = -1.24, p = 0.21 Beta = -0.09, z = -3.01, p = 0.003 
 
Beta: Standardized regression coefficient  
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